Zacks.com on MSN2 小时
Merck Halts Second PAH Drug Study Early on Strong Efficacy Results
Merck MRK has decided to stop the phase III HYPERION study early. The study evaluates MRK’s pulmonary arterial hypertension ...
PharmiWeb11 小时
Merck Announces Decision to Stop Phase 3 HYPERION Trial Evaluating WINREVAIR ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today the Phase 3 HYPERION study evaluating WINREVAIR (sotatercept-csrk) versus placebo (both in combination with ...
Daily14 小时
Merck to stop trial evaluating Winrevair pulmonary arterial hypertension early
Rahway: Merck, known as MSD outside of the United States and Canada, has announced the Phase 3 HYPERION study evaluating ...
Pharmabiz16 小时
Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis
Merck to stop phase 3 HYPERION trial evaluating Winrevair early and move to final analysis: Rahway, New Jersey Friday, January 31, 2025, 10:00 Hrs [IST] Merck, known as MSD outsid ...
来自MSN20 小时
MSD halts Winrevair trial due to success of previous study
MSD said that its sotatercept steering committee called for the trial to end as patients are moved to the ongoing open-label ...